Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox vs Desferrioxamine in β-thalassemia major
NCT06468423Completed
- Sponsor
- RESnTEC (Research and Technology) Ltd
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of deferasirox in iron overload, sponsored by RESnTEC (Research and Technology) Ltd. Primary endpoint: Mean Serum Ferritin Levels at 6 months. Started Jan 2023; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT06468423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468423.